No Data
No Data
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Supernus Pharmaceuticals' (NASDAQ:SUPN) Investors Will Be Pleased With Their Favorable 60% Return Over the Last Five Years
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $44
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Supernus Pharmaceuticals (SUPN)
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease